224:(H6PD). H6PD is distinct from its isozyme, glucose-6-phosphate dehydrogenase (G6PDH) in that G6PDH is a cytolytic enzyme and draws from a separate pool of NAD+. H6PD is also capable of catalyzing the oxidation of several phosphorylated hexoses, while G6PDH shows affinity for glucose, specifically. The enzyme cortisone reductase exists in a tightly controlled reaction space, facing the lumen of the endoplasmic reticulum of cells in the liver and lungs. NADH produced by hexose-6-phosphate is delivered directly to the catalytic site of cortisone reductase. If NADH production is limited, then cortisone reductase is also capable of catalysing the reverse reaction taking circulating cortisol and reducing it to cortisone. Dysregulation of hexose-6-phosphate dehydrogenase occurs as a result of gene mutation. Cortisol is important in signalling inhibition of
200:
192:
113:
37:
896:
Charitidou, C; Farmakiotis, D; Zournatzi, V; Pidonia, I; Pegiou, T; Karamanis, N; Hatzistilianou, M; Katsikis, I; Panidis, D (2008). "The administration of estrogens, combined with anti-androgens, has beneficial effects on the hormonal features and asymmetric dimethyl-arginine levels, in women with
207:
In a healthy body, blood cortisone and cortisol levels are roughly equimolar. Cortisone reductase deficiency leads to an elevated level of inert cortisone to active cortisol in adipose tissue. Cortisone reductase deficiency is caused by dysregulation of the 11β-hydroxysteroid dehydrogenase type 1
182:
Inactivating mutations in the H6PD gene lead to a lowered supply of NADH, causing cortisone reductase to catalyze the reaction from cortisol to cortisone. This is the most common manifestation of CRD. It has been shown that CRD can be caused by mutations in the HSD11B1 gene as well, specifically
240:
relies on blood levels of cortisol to act as negative feedback. Low levels of blood cortisol leads to release of
Corticotrope Releasing Hormone (CRH) activating the anterior pituitary and signalling the release of Adrenocorticotropic Hormone (ACTH), stimulating the adrenal gland to make more
169:
Cortisol inhibition, and as a result, excess androgen release can lead to a variety of symptoms. Other symptoms come about as a result of increased levels of circulating androgen. Androgen is a steroid hormone, generally associated with development of male sex organs and secondary male sex
591:
Draper, N; Walker, E. A.; Bujalska, I. J.; Tomlinson, J. W.; Chalder, S. M.; Arlt, W; Lavery, G. G.; Bedendo, O; Ray, D. W.; Laing, I; Malunowicz, E; White, P. C.; Hewison, M; Mason, P. J.; Connell, J. M.; Shackleton, C. H.; Stewart, P. M. (2003). "Mutations in the genes encoding
453:
Draper, N; Walker, E. A.; Bujalska, I. J.; Tomlinson, J. W.; Chalder, S. M.; Arlt, W; Lavery, G. G.; Bedendo, O; Ray, D. W.; Laing, I; Malunowicz, E; White, P. C.; Hewison, M; Mason, P. J.; Connell, J. M.; Shackleton, C. H.; Stewart, P. M. (2003). "Mutations in the genes encoding
98:
in women. Cortisone
Reductase Deficiency alone has been reported in fewer than ten cases in total, all but one case were women. Elevated activity of 11β-HSD1 can lead to obesity or Type II Diabetes, because of the role of cortisol in carbohydrate metabolism and gluconeogenesis.
183:
mutations caused by K187N and R137C, affecting active site residue and disruption of salt bridges at the subunit interface of the dimer, respectively. In the K187N mutant, activity is abolished, and in the R137C mutant activity is greatly reduced, but not completely abolished.
261:
There is no treatment for cortisone reductase deficiency. Shots of cortisol are quickly metabolised into cortisone by the dysregulated 11β-HSD1 enzyme; however, symptoms can be treated. Treatment of hyperandrogenism can be done through prescription of
951:
174:(PCOS) in females. The symptoms of PCOS include excessive hair growth, oligomenorrhea, amenorrhea, and infertility. In men, cortisone reductase deficiency results in premature pseudopuberty, or sexual development before the age of nine.
360:
Pereira, C. D.; Azevedo, I; Monteiro, R; Martins, M. J. (2012). "11β-Hydroxysteroid dehydrogenase type 1: Relevance of its modulation in the pathophysiology of obesity, the metabolic syndrome and type 2 diabetes mellitus".
83:
Cortisol is a glucocorticoid that plays a variety of roles in many different biochemical pathways, including, but not limited to: gluconeogenesis, suppressing immune system responses and carbohydrate metabolism.
404:
Lavery, G. G.; Walker, E. A.; Tiganescu, A; Ride, J. P.; Shackleton, C. H.; Tomlinson, J. W.; Connell, J. M.; Ray, D. W.; Biason-Lauber, A; Malunowicz, E. M.; Arlt, W; Stewart, P. M. (2008).
199:
81:
in the presence of NADH as a co-factor. If levels of NADH are low, the enzyme catalyses the reverse reaction, from cortisol to cortisone, using NAD+ as a co-factor.
237:
91:
676:
Senesi, S; Csala, M; Marcolongo, P; Fulceri, R; Mandl, J; Banhegyi, G; Benedetti, A (2010). "Hexose-6-phosphate dehydrogenase in the endoplasmic reticulum".
406:"Steroid biomarkers and genetic studies reveal inactivating mutations in hexose-6-phosphate dehydrogenase in patients with cortisone reductase deficiency"
209:
70:
66:
719:
Hughes, K. A.; Manolopoulos, K. N.; Iqbal, J; Cruden, N. L.; Stimson, R. H.; Reynolds, R. M.; Newby, D. E.; Andrew, R; Karpe, F; Walker, B. R. (2012).
123:
228:
release from the pituitary. Reduced cortisol in circulation activates the H-P-A Axis to produce and release more cortisol, and therefore androgen.
195:
An overview of how cortisone reductase is driven by NADH production by hexose-6-phosphate and how it affects the HPA Axis in a healthy body.
963:
156:
592:
11beta-hydroxysteroid dehydrogenase type 1 and hexose-6-phosphate dehydrogenase interact to cause cortisone reductase deficiency".
454:
11beta-hydroxysteroid dehydrogenase type 1 and hexose-6-phosphate dehydrogenase interact to cause cortisone reductase deficiency".
253:
Diagnosis of cortisone reductase deficiency is done through analysis of cortisol to cortisone metabolite levels in blood samples.
191:
854:"Tissue-specific Cushing's syndrome, 11beta-hydroxysteroid dehydrogenases and the redefinition of corticosteroid hormone action"
318:"Tissue-specific Cushing's syndrome, 11beta-hydroxysteroid dehydrogenases and the redefinition of corticosteroid hormone action"
721:"Recycling between cortisol and cortisone in human splanchnic, subcutaneous adipose, and skeletal muscle tissues in vivo"
637:"Minireview: Hexose-6-phosphate dehydrogenase and redox control of 11{beta}-hydroxysteroid dehydrogenase type 1 activity"
497:
Lawson, A. J.; Walker, E. A.; Lavery, G. G.; Bujalska, I. J.; Hughes, B; Arlt, W; Stewart, P. M.; Ride, J. P. (2011).
225:
499:"Cortisone-reductase deficiency associated with heterozygous mutations in 11beta-hydroxysteroid dehydrogenase type 1"
138:
817:
Tomlinson, J. W.; Stewart, P. M. (2001). "Cortisol metabolism and the role of 11beta-hydroxysteroid dehydrogenase".
556:
Tomlinson, J. W.; Stewart, P. M. (2001). "Cortisol metabolism and the role of 11beta-hydroxysteroid dehydrogenase".
770:"Mutations of the hexose-6-phosphate dehydrogenase gene rarely cause hyperandrogenemic polycystic ovary syndrome"
171:
95:
220:, using NADH as a co-factor. The oxidative or reductive capacity of the enzyme is regulated by NADH produced by
1014:
992:
292:"Cortisone reductase deficiency | Genetic and Rare Diseases Information Center (GARD) – an NCATS Program"
130:
510:
170:
characteristics The symptoms associated with
Cortisone Reductase Deficiency are often linked with
701:
617:
479:
386:
914:
878:
834:
799:
750:
693:
658:
609:
573:
538:
471:
435:
378:
342:
49:
906:
868:
826:
789:
781:
740:
732:
685:
648:
601:
565:
528:
518:
463:
425:
417:
370:
332:
245:, which gives rise to the symptoms commonly associated with Cortisone Reductase Deficiency.
242:
87:
54:
910:
274:
hormone, both hormones in the pituitary, responsible for the production of testosterone.
514:
291:
241:
cortisol. In addition to cortisol, the adrenal gland also releases androgen, leading to
853:
794:
769:
745:
720:
533:
498:
430:
405:
317:
212:. The 11β-HSD1 enzyme is responsible for catalyzing the interconversion of circulating
1008:
374:
705:
621:
483:
390:
203:
Cortisone
Reductase Deficiency effects on HPA and body in presence of deficient H6PD
785:
267:
263:
271:
94:. The deficiency has been known to exhibit symptoms of other disorders such as
523:
213:
74:
918:
882:
838:
830:
803:
754:
697:
662:
613:
577:
569:
542:
475:
439:
382:
346:
943:
873:
337:
36:
987:
653:
636:
421:
217:
78:
689:
736:
955:
819:
Best
Practice & Research Clinical Endocrinology & Metabolism
558:
Best
Practice & Research Clinical Endocrinology & Metabolism
605:
467:
198:
190:
73:, a bi-directional enzyme, which catalyzes the interconversion of
968:
221:
106:
86:
One of the symptoms of cortisone reductase deficiency is
134:
410:
The
Journal of Clinical Endocrinology & Metabolism
635:
Hewitt, K. N.; Walker, E. A.; Stewart, P. M. (2005).
933:
978:
937:
48:
26:
21:
503:Proceedings of the National Academy of Sciences
8:
934:
266:. They do so by inhibiting the release of
35:
18:
872:
793:
744:
652:
532:
522:
429:
336:
157:Learn how and when to remove this message
129:Relevant discussion may be found on the
283:
67:11β-hydroxysteroid dehydrogenase type 1
44:11β-hydroxysteroid dehydrogenase type 1
141:to additional sources at this section.
69:enzyme (11β-HSD1), otherwise known as
911:10.1016/j.atherosclerosis.2007.03.002
7:
238:Hypothalamic-Pituitary-Adrenal axis
92:Hypothalamic–pituitary–adrenal axis
90:, resulting from activation of the
768:Qin, K; Rosenfield, R. L. (2011).
122:relies largely or entirely upon a
65:is caused by dysregulation of the
14:
861:European Journal of Endocrinology
325:European Journal of Endocrinology
897:the polycystic ovary syndrome".
375:10.1111/j.1463-1326.2012.01582.x
363:Diabetes, Obesity and Metabolism
222:hexose-6-phosphate dehydrogenase
111:
786:10.1016/j.steroids.2010.10.001
63:Cortisone reductase deficiency
22:Cortisone reductase deficiency
1:
226:adrenocorticotropic hormone
208:enzyme, otherwise known as
1031:
296:rarediseases.info.nih.gov
172:Polycystic Ovary Syndrome
96:Polycystic Ovary Syndrome
43:
34:
852:Stewart, P. M. (2003).
524:10.1073/pnas.1014934108
316:Stewart, P. M. (2003).
831:10.1053/beem.2000.0119
570:10.1053/beem.2000.0119
204:
196:
874:10.1530/eje.0.1490163
338:10.1530/eje.0.1490163
202:
194:
678:Biological Chemistry
654:10.1210/en.2005-0117
422:10.1210/jc.2008-0743
135:improve this article
30:HSD 11b1 deficiency
690:10.1515/BC.2009.146
515:2011PNAS..108.4111L
210:cortisone reductase
71:cortisone reductase
979:External resources
232:Effect on HPA Axis
205:
197:
103:Signs and symptoms
1002:
1001:
737:10.2337/db11-1345
167:
166:
159:
60:
59:
16:Medical condition
1022:
935:
923:
922:
893:
887:
886:
876:
858:
849:
843:
842:
814:
808:
807:
797:
765:
759:
758:
748:
716:
710:
709:
673:
667:
666:
656:
632:
626:
625:
588:
582:
581:
553:
547:
546:
536:
526:
494:
488:
487:
450:
444:
443:
433:
401:
395:
394:
357:
351:
350:
340:
322:
313:
307:
306:
304:
302:
288:
243:hyperandrogenism
162:
155:
151:
148:
142:
115:
114:
107:
88:hyperandrogenism
55:Medical genetics
39:
19:
1030:
1029:
1025:
1024:
1023:
1021:
1020:
1019:
1005:
1004:
1003:
998:
997:
974:
973:
946:
932:
927:
926:
899:Atherosclerosis
895:
894:
890:
856:
851:
850:
846:
816:
815:
811:
767:
766:
762:
718:
717:
713:
675:
674:
670:
634:
633:
629:
594:Nature Genetics
590:
589:
585:
555:
554:
550:
496:
495:
491:
456:Nature Genetics
452:
451:
447:
416:(10): 3827–32.
403:
402:
398:
359:
358:
354:
320:
315:
314:
310:
300:
298:
290:
289:
285:
280:
259:
251:
234:
189:
187:Pathophysiology
180:
163:
152:
146:
143:
137:by introducing
128:
116:
112:
105:
85:
82:
17:
12:
11:
5:
1028:
1026:
1018:
1017:
1015:Enzyme defects
1007:
1006:
1000:
999:
996:
995:
983:
982:
980:
976:
975:
972:
971:
960:
947:
942:
941:
939:
938:Classification
931:
930:External links
928:
925:
924:
888:
844:
809:
780:(1–2): 135–9.
760:
731:(6): 1357–64.
711:
668:
647:(6): 2539–43.
627:
606:10.1038/ng1214
583:
548:
509:(10): 4111–6.
489:
468:10.1038/ng1214
445:
396:
369:(10): 869–81.
352:
308:
282:
281:
279:
276:
258:
255:
250:
247:
233:
230:
188:
185:
179:
176:
165:
164:
147:September 2021
133:. Please help
119:
117:
110:
104:
101:
58:
57:
52:
46:
45:
41:
40:
32:
31:
28:
24:
23:
15:
13:
10:
9:
6:
4:
3:
2:
1027:
1016:
1013:
1012:
1010:
994:
990:
989:
985:
984:
981:
977:
970:
966:
965:
961:
958:
957:
953:
949:
948:
945:
940:
936:
929:
920:
916:
912:
908:
905:(2): 958–65.
904:
900:
892:
889:
884:
880:
875:
870:
866:
862:
855:
848:
845:
840:
836:
832:
828:
824:
820:
813:
810:
805:
801:
796:
791:
787:
783:
779:
775:
771:
764:
761:
756:
752:
747:
742:
738:
734:
730:
726:
722:
715:
712:
707:
703:
699:
695:
691:
687:
683:
679:
672:
669:
664:
660:
655:
650:
646:
642:
641:Endocrinology
638:
631:
628:
623:
619:
615:
611:
607:
603:
599:
595:
587:
584:
579:
575:
571:
567:
563:
559:
552:
549:
544:
540:
535:
530:
525:
520:
516:
512:
508:
504:
500:
493:
490:
485:
481:
477:
473:
469:
465:
461:
457:
449:
446:
441:
437:
432:
427:
423:
419:
415:
411:
407:
400:
397:
392:
388:
384:
380:
376:
372:
368:
364:
356:
353:
348:
344:
339:
334:
330:
326:
319:
312:
309:
297:
293:
287:
284:
277:
275:
273:
269:
265:
264:antiandrogens
256:
254:
248:
246:
244:
239:
231:
229:
227:
223:
219:
215:
211:
201:
193:
186:
184:
177:
175:
173:
161:
158:
150:
140:
136:
132:
126:
125:
124:single source
120:This section
118:
109:
108:
102:
100:
97:
93:
89:
80:
76:
72:
68:
64:
56:
53:
51:
47:
42:
38:
33:
29:
25:
20:
986:
962:
950:
902:
898:
891:
867:(3): 163–8.
864:
860:
847:
825:(1): 61–78.
822:
818:
812:
777:
773:
763:
728:
724:
714:
681:
677:
671:
644:
640:
630:
600:(4): 434–9.
597:
593:
586:
564:(1): 61–78.
561:
557:
551:
506:
502:
492:
462:(4): 434–9.
459:
455:
448:
413:
409:
399:
366:
362:
355:
331:(3): 163–8.
328:
324:
311:
299:. Retrieved
295:
286:
268:gonadotropin
260:
252:
235:
206:
181:
168:
153:
144:
121:
62:
61:
272:luteinizing
27:Other names
684:(1): 1–8.
278:References
301:5 October
257:Treatment
249:Diagnosis
214:cortisone
139:citations
131:talk page
75:cortisone
50:Specialty
1009:Category
988:Orphanet
919:17418849
883:12943516
839:11469811
804:21050867
774:Steroids
755:22511204
725:Diabetes
706:34649527
698:19804362
663:15774558
622:22772927
614:12858176
578:11469811
543:21325058
484:22772927
476:12858176
440:18628520
391:20241705
383:22321826
347:12943516
218:cortisol
178:Genetics
79:cortisol
959:: E25.8
795:3023921
746:3357308
534:3054023
511:Bibcode
431:2579651
993:168588
969:604931
917:
881:
837:
802:
792:
753:
743:
704:
696:
661:
620:
612:
576:
541:
531:
482:
474:
438:
428:
389:
381:
345:
857:(PDF)
702:S2CID
618:S2CID
480:S2CID
387:S2CID
321:(PDF)
964:OMIM
915:PMID
879:PMID
835:PMID
800:PMID
751:PMID
694:PMID
659:PMID
610:PMID
574:PMID
539:PMID
472:PMID
436:PMID
379:PMID
343:PMID
303:2019
270:and
236:The
952:ICD
907:doi
903:196
869:doi
865:149
827:doi
790:PMC
782:doi
741:PMC
733:doi
686:doi
682:391
649:doi
645:146
602:doi
566:doi
529:PMC
519:doi
507:108
464:doi
426:PMC
418:doi
371:doi
333:doi
329:149
216:to
77:to
1011::
991::
967::
956:10
913:.
901:.
877:.
863:.
859:.
833:.
823:15
821:.
798:.
788:.
778:76
776:.
772:.
749:.
739:.
729:61
727:.
723:.
700:.
692:.
680:.
657:.
643:.
639:.
616:.
608:.
598:34
596:.
572:.
562:15
560:.
537:.
527:.
517:.
505:.
501:.
478:.
470:.
460:34
458:.
434:.
424:.
414:93
412:.
408:.
385:.
377:.
367:14
365:.
341:.
327:.
323:.
294:.
954:-
944:D
921:.
909::
885:.
871::
841:.
829::
806:.
784::
757:.
735::
708:.
688::
665:.
651::
624:.
604::
580:.
568::
545:.
521::
513::
486:.
466::
442:.
420::
393:.
373::
349:.
335::
305:.
160:)
154:(
149:)
145:(
127:.
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.
